Shahariar Mohammed Fahim

Shahariar Mohammed Fahim

Auto-generated profile, based on publicly available information

Shahariar Mohammed Fahim

Institute for Clinical and Economic Review (ICER), Boston, MA 02108, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2023 in Journal of the American Pharmacists Association
Verified
Journal Article
Closed access
SFShahariar Mohammed Fahim
Shahariar Mohammed Fahim
Courtney S. Watts AlexanderCourtney S. Watts Alexander
Courtney S. Watts Alexander
JQJingjing Qian
Jingjing Qian
SNSurachat Ngorsuraches
Surachat Ngorsuraches
NHNatalie S. Hohmann
Natalie S. Hohmann
SWSalisa C Westrick
Salisa C Westrick

28 July 2022 in The Science of Diabetes Self-Management and Care
Verified
Journal Article
Closed access
JKJan Kavookjian
Jan Kavookjian
JLJacqueline B. LaManna
Jacqueline B. LaManna
PDPatricia Davidson
Patricia Davidson
JDJean W. Davis
Jean W. Davis
SFShahariar Mohammed Fahim
Shahariar Mohammed Fahim
CCCarla Cox
Carla Cox
Purpose: The persistent requirement of self-management for diabetes impacts quality of life (QoL), yet the literature for impact of diabetes self-management education and support (DSMES) on QoL in youth has not been synthesized and reported. The purpose of this review was to systematically identify and describe the state of the science exploring the impact of DSMES on self-reported QoL in youth with type 1 diabetes (T1DM) or type 2 diabetes (T2DM). Methods: A modified Cochrane review was conducted. Retained studies were published in the English language between January 1, 2007, and March 31, 2020. Included studies specified that the intervention had diabetes education addressing at least 1 or more of The Association of Diabetes Care & Education Specialists’ ADCES7 Self-Care BehaviorsTM (ADCES7™) and used an established self-reported QoL measure. Retained studies were assessed for risk of bias. Results: Eleven studies reported in 12 articles were retained. The interventions were primarily delivered to youth with T1DM or T2DM and included caregivers/families in some studies. The ADCES7™ were addressed across the retained studies. Five of the 11 studies assessed QoL as the primary outcome and 6 studies as a secondary outcome. Conclusion: To enhance the QoL outcomes and to provide insight into how to positively impact self-perceptions of QoL, ongoing generic and diabetes-specific QoL assessments are warranted for youth with T1DM or T2DM. Further research is needed in structured DSMES programs to help reduce variability in research designs, methods, measures, and outcomes to generate evidence for best practices that can be translated and disseminated into real-world settings.

4 May 2022 in Journal of Medical Economics
Verified
Journal Article
Open access
NPN. Poudel
N. Poudel
SFS. M. Fahim
S. M. Fahim
JQJ. Qian
J. Qian
KGKimberly Garza
Kimberly Garza
NCNathorn Chaiyakunapruk
Nathorn Chaiyakunapruk
SNS. Ngorsuraches
S. Ngorsuraches
1) to descriptively compare the selected elements of valuation methods for EQ-5D-5L value set studies, 2) to compare the characteristics of the value sets, and 3) to examine the associations betwee...

27 December 2018 in Expert Opinion on Drug Safety
Verified
Journal Article
Closed access
SFShahariar Mohammed Fahim
Shahariar Mohammed Fahim
AMAhmed Ullah Mishuk
Ahmed Ullah Mishuk
NCNing Cheng
Ning Cheng
RHRichard Hansen
Richard Hansen
ACAngela I. Calderón
Angela I. Calderón
JQJingjing Qian
Jingjing Qian
Background: To examine adverse event (AE) reporting patterns for concomitant Botanical Dietary Supplements (BDS) and anticancer drugs. Research Design and Methods: Using the 2004-2015 U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database, AEs involving commonly used BDS and anticancer drugs (categorized into CYP3A4 interactive and CYP3A4 non-interactive) were focused on. Disproportionality analyses using reporting odds ratios (RORs) assessed the relative reporting rates of 1) serious AEs (i.e., mortality and morbidity) with concomitant use of BDS (overall and by type) and anticancer drugs compared to anticancer drugs only; and 2) AEs by specific System Organ Classes (SOCs). Results: A total of 3,264 AEs were reported involving concomitant BDS and CYP3A4 interactives, and 3,885 involving concomitant BDS and non-interactive anticancer drugs. ROR of serious AEs with concomitant all BDS and anticancer drugs compared to anticancer drugs alone showed a potential protective signal (ROR=0.65, 95% CI=0.62,0.68), but ROR for açaí and non-interactive anticancer drugs indicated potential risk (ROR=1.70, 95% CI=1.01,2.86). Heterogeneity of reporting patterns of AEs related to certain SOCs was observed for use of BDS along with anticancer drugs. Conclusion: This study identified potential protective and risk signals for AEs with concomitant use of BDS and anticancer drugs.

21 February 2024 in Personalized Medicine
Verified
Journal Article
Closed access
SFShahariar Mohammed Fahim
Shahariar Mohammed Fahim
SWSalisa C Westrick
Salisa C Westrick
JQJingjing Qian
Jingjing Qian
SNSurachat Ngorsuraches
Surachat Ngorsuraches
CACourtney S Watts Alexander
Courtney S Watts Alexander
NHNatalie S Hohmann
Natalie S Hohmann
Aim: To understand awareness, knowledge and preferences regarding genetic testing among the USA general public. Methods: A cross-sectional online survey using a Qualtrics Panel. Results: Among 1600... Plain language summary What is this study about? This study presents a large online survey among the USA general public to understand their awareness, knowledge and preferences about genetic testin...

1 September 2020 in Research in Social and Administrative Pharmacy
Verified
Journal Article
Closed access
SFShahariar Mohammed Fahim
Shahariar Mohammed Fahim
SNSurachat Ngorsuraches
Surachat Ngorsuraches